Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda ® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in ...

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting Apr. 23, 2025 10:28 ...

The poster will showcase the design and ongoing progress of its Phase 1 study of CID-078 (NCT06577987), a first-in-class, oral macrocycle cyclin A/B RxL inhibitor.

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

MBrace Therapeutics Presents Trial in Progress Poster for Lead Antibody-Drug Conjugate Program at 2024 ASCO Annual Meeting May 31, 2024 08:30 AM Eastern Daylight Time ...

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting Provided by Business Wire May 12, 2025, 11:05:00 AM ...

Rakuten Medical Announces Trial in Progress Poster Presentation at ASCO 2025 and Enrollment Expansion to Taiwan for Global Phase 3 ASP-1929-381 Provided by PR Newswire May 22, 2025, 11:05:00 PM ...